Medicus Pharma Ltd.(MDCX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MDCX Medicus Pharma Ltd.

休市中 10-23 16:00:00 EDT

2.50

-0.12

-4.58%

盘后2.58

+0.08+3.20%

19:54 EDT

最高2.61	最低2.50	成交量8.42万
今开2.60	昨收2.62	日振幅4.20%
总市值472.95万	流通市值410.56万	总股本189.18万
成交额21.45万	换手率5.12%	流通股本164.23万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MDCX","market":"US","secType":"STK","nameCN":"Medicus Pharma Ltd.","latestPrice":2.5,"timestamp":1792785600000,"preClose":2.62,"halted":0,"volume":84164,"hourTrading":{"tag":"盘后","latestPrice":2.58,"preClose":2.5,"latestTime":"19:54 EDT","volume":2259,"amount":5809.5288,"timestamp":1792799642846,"change":0.08,"changeRate":0.032,"amplitude":0.04},"delay":0,"changeRate":-0.045801526717557293,"floatShares":1642254,"shares":1891800,"eps":-82.98446,"marketStatus":"休市中","change":-0.12,"latestTime":"10-23 16:00:00 EDT","open":2.6,"high":2.61,"low":2.5,"amount":214461.04056280002,"amplitude":0.041985,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-82.98446,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1793001600000},"marketStatusCode":7,"adr":0,"listingDate":1731560400000,"exchange":"NASDAQ","adjPreClose":2.62,"preHourTrading":{"tag":"盘前","latestPrice":2.59,"preClose":2.62,"latestTime":"09:29 EDT","volume":116,"amount":299.5912048,"timestamp":1792762177020,"change":-0.03,"changeRate":-0.01145,"amplitude":0.032405},"postHourTrading":{"tag":"盘后","latestPrice":2.58,"preClose":2.5,"latestTime":"19:54 EDT","volume":2259,"amount":5809.5288,"timestamp":1792799642846,"change":0.08,"changeRate":0.032,"amplitude":0.04},"volumeRatio":1.4281593345417969},"requestUrl":"/m/hq/s/MDCX","defaultTab":"news","newsList":[{"id":"1189169859","title":"Medicus Pharma宣布Skinject®在戈林综合征领域的独家开发重点，经商业、临床及监管全面评估后敲定","url":"https://stock-news.laohu8.com/highlight/detail?id=1189169859","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189169859?lang=zh_cn&edition=full","pubTime":"2026-09-21 19:31","pubTimestamp":1789990276,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.近日正式宣布，将Skinject的开发方向独家聚焦于戈林综合征适应症。这一战略决策是在对商业前景、临床证据及监管路径进行系统评估之后作出的，标志着公司在该罕见病领域的资源投入进一步集中与深化。综合考量后，管理层认定戈林综合征是Skinject最具差异化优势的开发赛道。Medicus Pharma认为，Skinject有望填补这一治疗空白，为该患者群体带来新的选择。Medicus Pharma此番战略调整，展现出其对研发管线的审慎梳理与长期布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135292318","title":"Medicus Pharma宣布终止与Yorkville的备用股权购买协议，9月11日生效——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1135292318","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135292318?lang=zh_cn&edition=full","pubTime":"2026-09-14 20:08","pubTimestamp":1789387690,"startTime":"0","endTime":"0","summary":"Medicus Pharma近日向美国证券交易委员会（SEC）提交文件，正式宣布终止其与Yorkville签订的一项备用股权购买协议。据悉，该协议的终止将在2026年9月11日正式生效。此举标志着两家机构之间现有融资安排画上了句号。文件内容简明扼要，未详细说明终止的具体原因，但已引发市场对该公司后续资本运作策略的广泛猜测。Medicus Pharma这一决定，无疑将为公司未来的财务路径增添新的变数与看点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131081188","title":"Medicus Pharma发布Skinject®二期临床试验最终报告摘要：确认200ΜG D-Mna贴片为主要研发剂量","url":"https://stock-news.laohu8.com/highlight/detail?id=1131081188","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131081188?lang=zh_cn&edition=full","pubTime":"2026-09-10 19:32","pubTimestamp":1789039958,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.近日公布了其Skinject二期临床试验的最终临床研究报告摘要，这一里程碑式的成果明确了200ΜG D-Mna贴片作为主导研发剂量的地位。作为一家专注于皮肤科创新疗法的生物制药企业，Medicus Pharma此次公布的结果或将对其未来的注册临床试验设计产生深远影响。该CSR摘要的发布，无疑为投资者和医学界观察这一候选药物的进展提供了关键的参考节点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664687724","title":"MEDICUS PHARMA股价下跌29.8%；公司与辉瑞就实验性癌症疗法达成授权协议。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664687724","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664687724?lang=zh_cn&edition=full","pubTime":"2026-09-03 21:42","pubTimestamp":1788442933,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","PFE","LU1894683348.USD","LU0058720904.USD","BK4007","LU2596442595.SGD","LU1894683264.USD","LU0985481810.HKD","IE00B19Z3581.USD","SG9999002232.USD","IE00BBT3K403.USD","IE00B3T34201.USD","IE00B19Z3B42.SGD","SG9999003800.SGD","SG9999001176.USD","LU0456855351.SGD","LU1023059063.AUD","OZEM","MDCX","IE00BLSP4452.SGD","LU0225284248.USD","LU0225771236.USD","IE0002270589.USD","IE000M9KFDE8.USD","LU0306807586.USD","LU1057294990.SGD","BK4585","LU1066053197.SGD","BK4592","LU1066051498.USD","SGXZ57979304.SGD","BK4533","BK4534","LU0868494617.USD","LU0170899867.USD","IE00BLSP4239.USD","SG9999001176.SGD","SG9999011175.SGD","LU0234572021.USD","LU1883839398.USD","BK4550","LU0122379950.USD","LU0321505439.SGD","LU0321505868.SGD","BK4568","BK4581","LU0306806265.USD","SG9999002224.SGD","BK4599","LU0289739699.SGD","BK4588","SG9999013999.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159628812","title":"Medicus Pharma盘前股价大跌20.5%，与辉瑞达成实验性癌症疗法授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1159628812","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159628812?lang=zh_cn&edition=full","pubTime":"2026-09-03 21:04","pubTimestamp":1788440685,"startTime":"0","endTime":"0","summary":"Medicus Pharma股价在盘前交易时段重挫20.5%。与此同时，该公司宣布与制药巨头辉瑞签署了一项授权协议，涉及一款尚处于实验阶段的癌症治疗药物。这一消息引发市场剧烈反应，投资者对该合作协议的条款及潜在影响迅速作出评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU1023059063.AUD","OZEM","BK4581","IE00B19Z3B42.SGD","LU0122379950.USD","LU0170899867.USD","LU1066051498.USD","LU1883839398.USD","SG9999002232.USD","LU0985481810.HKD","LU0289739699.SGD","SGXZ57979304.SGD","IE000M9KFDE8.USD","LU0321505439.SGD","LU1066053197.SGD","LU1894683264.USD","BK4568","LU0234572021.USD","BK4533","SG9999013999.USD","BK4599","IE00B19Z3581.USD","LU0225771236.USD","MDCX","LU0058720904.USD","SG9999001176.SGD","IE00BBT3K403.USD","IE00BLSP4239.USD","LU0321505868.SGD","BK4139","BK4007","BK4585","IE00B3T34201.USD","LU0306806265.USD","LU0868494617.USD","BK4588","PFE","IE0002270589.USD","LU1057294990.SGD","SG9999011175.SGD","LU0456855351.SGD","SG9999003800.SGD","LU0306807586.USD","IE00BLSP4452.SGD","SG9999001176.USD","LU0225284248.USD","LU1894683348.USD","LU2596442595.SGD","BK4550","SG9999002224.SGD","BK4592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187458964","title":"Medicus Pharma于2026年9月2日与辉瑞签署共同开发及许可协议——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1187458964","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187458964?lang=zh_cn&edition=full","pubTime":"2026-09-03 20:06","pubTimestamp":1788437176,"startTime":"0","endTime":"0","summary":"2026年9月2日，Medicus Pharma与制药巨头辉瑞达成了一项共同开发及许可协议。这一消息源自该公司向美国证券交易委员会提交的官方文件。\n根据SEC文件显示，Medicus Pharma于当日正式与辉瑞签署合作协议。然而，文件并未详细披露该协议的具体条款及涉及的药物领域，外界对此充满猜测。\n投资者正密切关注这一合作动态，Medicus Pharma的此次战略布局也被视为其发展的重要里程碑。辉瑞作为全球领先的制药企业，选择与Medicus Pharma联手，无疑为后者注入了强劲的发展动力。\n关于该合作协议的更多细节，尚待双方进一步公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002232.USD","LU0122379950.USD","BK4588","BK4592","LU1057294990.SGD","LU0321505439.SGD","LU0306807586.USD","IE00BBT3K403.USD","LU0456855351.SGD","BK4568","LU1894683348.USD","PFE","LU0868494617.USD","SG9999002224.SGD","IE00BLSP4452.SGD","BK4007","SG9999001176.SGD","LU1023059063.AUD","IE00BLSP4239.USD","LU1883839398.USD","LU1894683264.USD","OZEM","SG9999001176.USD","SG9999013999.USD","BK4533","BK4599","IE0002270589.USD","BK4581","BK4550","LU0058720904.USD","IE00B19Z3581.USD","LU0225284248.USD","LU0289739699.SGD","LU0225771236.USD","LU0234572021.USD","SG9999003800.SGD","LU1066053197.SGD","IE000M9KFDE8.USD","MDCX","LU0170899867.USD","IE00B19Z3B42.SGD","LU0985481810.HKD","LU0321505868.SGD","BK4585","BK4139","LU2596442595.SGD","SG9999011175.SGD","LU0306806265.USD","SGXZ57979304.SGD","LU1066051498.USD","BK4534","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107772972","title":"新闻稿：Medicus Pharma 任命 Faisal Mehmud 博士为英国子公司 Antev Limited 首席执行官","url":"https://stock-news.laohu8.com/highlight/detail?id=1107772972","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107772972?lang=zh_cn&edition=full","pubTime":"2026-08-03 19:33","pubTimestamp":1785756837,"startTime":"0","endTime":"0","summary":"费城，2026年8月3日——生物科技与生命科学公司 Medicus Pharma Ltd.今日宣布，任命Faisal Mehmud医学博士、皇家内科医师学会会员为英国子公司Antev Limited的首席执行官，自2026年8月30日起生效。该公司专注于推进新型且潜在颠覆性治疗资产的临床开发项目。Mehmud博士将继续担任Medicus的首席医疗官和Antev的联合主席。此次任命进一步加强了Medicus的整合领导架构。Mehmud博士接替了Amit Kohli，后者自2025年8月29日Medicus完成对Antev的收购以来一直担任临时首席执行官。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4211","UK","BK4139","BK4567","MRCP","UBCP","R","BCC","BK4528","BK4205","BK4104","MDCX","BK4233","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127932291","title":"Medicus Pharma任命DR. Faisal Mehmud为英国Antev Limited首席执行官","url":"https://stock-news.laohu8.com/highlight/detail?id=1127932291","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127932291?lang=zh_cn&edition=full","pubTime":"2026-08-03 19:31","pubTimestamp":1785756684,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.（简称Medicus Pharma）正式宣布，已任命DR. Faisal Mehmud担任其旗下位于英国的子公司Antev Limited的首席执行官一职。这一重要人事变动，标志着公司在全球战略布局中迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177582386","title":"Medicus Pharma获阿联酋卫生部门批准，推进Teverelix Precision-E2 2a期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1177582386","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177582386?lang=zh_cn&edition=full","pubTime":"2026-07-31 19:31","pubTimestamp":1785497475,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.宣布，阿联酋卫生部门已正式批准其开展Teverelix的Precision-E2 2a期临床研究。这一授权标志着该药物研发进程中的重要里程碑。获批的临床试验将聚焦于评估Teverelix的疗效与安全性，为后续研究奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149302811","title":"Medicus Pharma 获FDA批准：针对戈林综合征患者的Skinject®关键注册研究可启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1149302811","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149302811?lang=zh_cn&edition=full","pubTime":"2026-07-27 20:18","pubTimestamp":1785154690,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.（MDCX）近日迎来重大里程碑——美国食品药品监督管理局（FDA）已正式发出“研究可推进”函件，为其针对戈林综合征患者的NDA注册性Skinject®研究亮起绿灯。这一关键进展，标志着该药物的临床开发迈入新阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153699376","title":"Medicus Pharma获FDA积极反馈及中心IRB批准，开展优化版Teverelix®治疗急性尿潴留二期新研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1153699376","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153699376?lang=zh_cn&edition=full","pubTime":"2026-07-16 19:31","pubTimestamp":1784201518,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.宣布，其针对急性尿潴留的优化版Teverelix®二期新研究已获得美国食品药品监督管理局（FDA）的积极反馈以及中心机构审查委员会（IRB）的批准。这一关键进展标志着该创新疗法向临床开发迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126634681","title":"Medicus Pharma宣布向美国食品药品监督管理局提交Skinject®用于戈林综合征的罕见儿科疾病认定申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1126634681","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126634681?lang=zh_cn&edition=full","pubTime":"2026-06-15 19:31","pubTimestamp":1781523074,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.（MDCX）已正式向美国食品药品监督管理局（FDA）提交申请，为其在研产品Skinject®寻求戈林综合征适应症的罕见儿科疾病认定。这一认定若获批准，将有望为患有此种罕见遗传性皮肤疾病的儿童患者带来新的治疗希望，并可能使公司在后续的研发与商业化进程中享有相应的政策激励。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110064382","title":"Medicus Pharma推进Teverelix®项目进入注册开发阶段，针对高心血管风险前列腺癌患者完成关键欧洲提交","url":"https://stock-news.laohu8.com/highlight/detail?id=1110064382","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110064382?lang=zh_cn&edition=full","pubTime":"2026-06-08 19:33","pubTimestamp":1780918414,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. 已将其Teverelix项目推进至注册开发阶段，旨在针对伴有高心血管风险的前列腺癌患者。这一进展的关键标志是公司已向欧洲监管机构提交了关键文件。Teverelix项目专注于满足这一特定患者群体的医疗需求，他们因心血管并发症风险较高，在治疗选择上面临更大挑战。下一步，公司将与监管机构密切合作，以确定后续的开发路径。这一战略举措有望为Medicus Pharma在该治疗领域建立重要地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113733033","title":"Medicus Pharma公布预设扩展二期Sknjct-003数据分析结果 显示显著剂量效应","url":"https://stock-news.laohu8.com/highlight/detail?id=1113733033","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113733033?lang=zh_cn&edition=full","pubTime":"2026-05-06 19:37","pubTimestamp":1778067449,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.最新披露的预设扩展二期临床试验Sknjct-003数据分析结果证实，其研究药物存在明确的剂量-效应关系。该数据进一步验证了治疗方案的有效性，为后续临床开发提供重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107238761","title":"Medicus Pharma Ltd. 旗下D-Mna展现良好安全性特征 未出现药物相关严重不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1107238761","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107238761?lang=zh_cn&edition=full","pubTime":"2026-05-06 19:34","pubTimestamp":1778067254,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. 近日公布其研究药物D-Mna的临床试验数据，结果显示该药物表现出良好的安全性特征。在整个试验过程中，未观察到任何与药物相关的严重不良事件。\n这一积极数据为D-Mna的后续临床开发奠定了坚实基础，凸显了其在安全性方面的显著优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512488091","title":"Citius Oncology, Inc.盘中异动 股价大涨5.08%报1.24美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512488091","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512488091?lang=zh_cn&edition=full","pubTime":"2025-02-19 22:44","pubTimestamp":1739976299,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日22时44分，Citius Oncology, Inc.股票出现异动，股价大幅拉升5.08%。截至发稿，该股报1.24美元/股，成交量152股，换手率0.00%，振幅0.00%。Citius Oncology, Inc.股票所在的制药行业中，整体涨幅为0.63%。Citius Oncology, Inc.公司简介：Citius Oncology Inc 是一家专业制药公司，致力于针对肿瘤产品未满足需求的重症护理产品的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219224459abd50140&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219224459abd50140&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MDCX","BK4139","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512416604","title":"Talphera, Inc.盘中异动 股价大跌5.97%报0.630美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512416604","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512416604?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:52","pubTimestamp":1739890371,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时52分，Talphera, Inc.股票出现异动，股价急速下挫5.97%。截至发稿，该股报0.630美元/股，成交量1.0769万股，换手率0.06%，振幅0.00%。Talphera, Inc.股票所在的制药行业中，整体涨幅为1.80%。Talphera, Inc.公司简介：Talphera Inc. 是一家制药公司，专注于在医疗监督环境中使用的疗法的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218225251a24ab199&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218225251a24ab199&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TLPH","MDCX","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511694810","title":"Talphera, Inc.盘中异动 股价大涨7.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511694810","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511694810?lang=zh_cn&edition=full","pubTime":"2025-02-14 22:36","pubTimestamp":1739543783,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日22时36分，Talphera, Inc.股票出现异动，股价大幅拉升7.75%。Talphera, Inc.股票所在的制药行业中，整体跌幅为0.44%。其相关个股中，Petros Pharmaceuticals, Inc.、Flora Growth Corp.、Medicus Pharma Ltd.涨幅较大，Cbdmd, Inc.、大自然药业、Petros Pharmaceuticals, Inc.较为活跃，换手率分别为6.47%、6.17%、3.22%，振幅较大的相关个股有Cbdmd, Inc.、Medicus Pharma Ltd.、Petros Pharmaceuticals, Inc.，振幅分别为9.12%、8.12%、6.26%。Talphera, Inc.公司简介：Talphera Inc. 是一家制药公司，专注于在医疗监督环境中使用的疗法的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021422362396231c78&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021422362396231c78&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PTPI","BK4007","TLPH","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2504914528","title":"Shuttle Pharmaceuticals Holdings, Inc.盘中异动 早盘股价大涨9.38%报0.920美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504914528","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2504914528?lang=zh_cn&edition=full","pubTime":"2025-01-16 23:47","pubTimestamp":1737042461,"startTime":"0","endTime":"0","summary":"北京时间2025年01月16日23时47分，Shuttle Pharmaceuticals Holdings, Inc.股票出现波动，股价大幅拉升9.38%。截至发稿，该股报0.920美元/股，成交量1559股，换手率0.04%，振幅0.55%。Shuttle Pharmaceuticals Holdings, Inc.股票所在的制药行业中，整体涨幅为0.51%。Shuttle Pharmaceuticals Holdings, Inc.公司简介：Shuttle Pharmaceuticals Holdings Inc 是一家临床阶段的制药公司，利用我们的专有技术开发旨在治愈癌症的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250116234742a22471b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250116234742a22471b3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MDCX","SHPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2488975317","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 股价大跌5.13%报20.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488975317","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2488975317?lang=zh_cn&edition=full","pubTime":"2024-12-04 04:31","pubTimestamp":1733257905,"startTime":"0","endTime":"0","summary":"北京时间2024年12月04日04时31分，Kiniksa Pharmaceuticals, Ltd.股票出现波动，股价急速跳水5.13%。Kiniksa Pharmaceuticals, Ltd.股票所在的制药行业中，整体涨幅为0.91%。其相关个股中，Citius Oncology, Inc.、Medicus Pharma Ltd.、Sunshine Biopharma Inc C/Wts 涨幅较大，Citius Oncology, Inc.、Painreform Ltd.、大自然药业较为活跃，换手率分别为140.57%、40.75%、39.33%，振幅较大的相关个股有Citius Oncology, Inc.、Medicus Pharma Ltd.、Sunshine Biopharma Inc C/Wts ，振幅分别为116.67%、45.51%、32.53%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals International PLC是一家处于临床阶段的生物制药公司，致力于发现、收购、开发和商业化治疗衰弱性疾病患者的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204043145971b6d22&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204043145971b6d22&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","KNSA","MDCX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.medicuspharma.com","stockEarnings":[{"period":"1week","weight":-0.2308},{"period":"1month","weight":-0.6863},{"period":"3month","weight":-0.8649},{"period":"6month","weight":-0.8412},{"period":"1year","weight":-0.9794},{"period":"ytd","weight":-0.9673}],"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0285},{"period":"6month","weight":0.0645},{"period":"1year","weight":0.1313},{"period":"ytd","weight":0.1145}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Medicus Pharma Ltd.于2008年4月30日根据加拿大安大略省法律成立。该公司是一家处于临床阶段的多战略生物技术/生命科学公司，专注于投资和加速新型和潜在颠覆性治疗资产的临床开发项目。该公司研究了所有治疗领域的机会，这些领域存在未满足的需求，需要提高患者的安全性和疗效。该公司正在机会主义地探索通过合格和增值的收购和合作来扩大其药物开发渠道。","exchange":"NASDAQ","name":"Medicus Pharma Ltd.","nameEN":"Medicus Pharma Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Medicus Pharma Ltd.(MDCX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Medicus Pharma Ltd.(MDCX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Medicus Pharma Ltd.,MDCX,Medicus Pharma Ltd.股票,Medicus Pharma Ltd.股票老虎,Medicus Pharma Ltd.股票老虎国际,Medicus Pharma Ltd.行情,Medicus Pharma Ltd.股票行情,Medicus Pharma Ltd.股价,Medicus Pharma Ltd.股市,Medicus Pharma Ltd.股票价格,Medicus Pharma Ltd.股票交易,Medicus Pharma Ltd.股票购买,Medicus Pharma Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Medicus Pharma Ltd.(MDCX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Medicus Pharma Ltd.(MDCX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}